after reconstitution, refrigerate at 28 C (35.646.4 F) and use within ~4 weeks
Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies, including Hims & Hers and other compounding pharmacies, as similar alternatives to FDA-approved drugs. The agency said the actions are intended to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy. The agency also emphasized ongoing concerns around promotional claims and direct-to-consumer messaging, building on the The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025, the agency said
Thalmann GN, Rhee H, Sikes RA, Pathak S, Multani A, Zhau HE et al
Its functional consequences may be reflected in the status of fat-soluble vitamins and related mineral homeostasis, particularly in individuals with pre-existing metabolic vulnerability
